THE first AND only fully human il-17a antagonist APPROVED for

moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis
Reference: Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.